O	0	7	Effects
O	8	10	of
B-intervention	11	25	Intraoperative
I-intervention	26	29	Low
I-intervention	29	30	-
I-intervention	30	34	Dose
I-intervention	35	43	Ketamine
O	44	46	on
O	47	57	Persistent
B-condition	58	70	Postsurgical
I-condition	71	75	Pain
O	76	81	after
O	82	88	Breast
O	89	95	Cancer
O	96	103	Surgery
O	103	104	:
O	105	106	A
O	107	118	Prospective
O	118	119	,
O	120	130	Randomized
O	130	131	,
O	132	142	Controlled
O	142	143	,
O	144	150	Double
O	150	151	-
O	151	156	Blind
O	157	162	Study
O	162	163	.

O	164	172	Compared
O	173	175	to
O	176	181	acute
O	182	194	postsurgical
O	195	199	pain
O	199	200	,
O	201	208	studies
O	209	218	regarding
O	219	222	the
O	223	227	role
O	228	230	of
O	231	239	ketamine
O	240	242	in
O	243	253	persistent
O	254	266	postsurgical
O	267	271	pain
O	272	273	(
O	273	277	PPSP
O	277	278	)
O	279	282	are
O	283	290	limited
O	290	291	.

O	292	295	The
O	296	299	aim
O	300	302	of
O	303	307	this
O	308	316	clinical
O	317	322	trial
O	323	326	was
O	327	329	to
O	330	334	test
O	335	337	if
O	338	352	intraoperative
O	353	356	low
O	356	357	-
O	357	361	dose
O	362	370	ketamine
O	371	378	without
O	379	392	postoperative
O	393	401	infusion
O	402	407	would
O	408	414	reduce
O	415	419	PPSP
O	420	431	development
O	432	437	after
O	438	444	breast
O	445	451	cancer
O	452	459	surgery
O	459	460	.

O	461	463	We
O	464	468	used
O	469	470	a
O	471	481	randomized
O	481	482	,
O	483	489	double
O	489	490	-
O	490	497	blinded
O	497	498	,
O	499	506	placebo
O	507	512	study
O	513	519	design
O	519	520	.

O	521	525	This
O	526	531	study
O	532	535	was
O	536	545	conducted
O	546	548	at
O	549	554	Pusan
O	555	563	National
O	564	574	University
O	575	583	Hospital
O	583	584	,
B-location	585	593	Republic
I-location	594	596	of
I-location	597	602	Korea
O	602	603	,
O	604	611	between
O	612	620	December
O	621	625	2013
O	626	629	and
O	630	636	August
O	637	641	2016
O	641	642	.

O	643	644	A
O	645	650	total
O	651	653	of
B-total-participants	654	657	184
B-eligibility	658	666	patients
I-eligibility	667	676	scheduled
I-eligibility	677	680	for
I-eligibility	681	687	breast
I-eligibility	688	694	cancer
I-eligibility	695	702	surgery
O	703	707	were
O	708	716	randomly
O	717	725	assigned
O	726	728	to
O	729	735	either
O	736	739	the
B-control	740	747	control
O	748	750	or
O	751	759	ketamine
O	760	765	group
O	765	766	.

O	767	773	Before
O	774	778	skin
O	779	787	incision
O	787	788	,
O	789	790	a
O	791	796	bolus
O	797	798	(
O	798	799	0
O	799	800	.
O	800	801	5
O	802	804	mg
O	804	805	/
O	805	807	kg
O	808	810	of
O	811	819	ketamine
O	820	822	or
O	823	830	placebo
O	830	831	)
O	831	832	,
O	833	841	followed
O	842	844	by
O	845	846	a
O	847	857	continuous
O	858	866	infusion
O	867	868	(
O	868	869	0
O	869	870	.
O	870	872	12
O	873	875	mg
O	875	876	/
O	876	878	kg
O	878	879	/
O	879	880	h
O	881	883	of
O	884	892	ketamine
O	893	895	or
O	896	903	placebo
O	903	904	)
O	904	905	,
O	906	909	was
O	910	922	administered
O	923	928	until
O	929	932	the
O	933	936	end
O	937	939	of
O	940	943	the
O	944	951	surgery
O	951	952	.

O	953	956	The
O	957	965	patients
O	966	970	were
O	971	982	interviewed
O	983	986	via
O	987	996	telephone
O	997	998	1
O	998	999	,
O	1000	1001	3
O	1001	1002	,
O	1003	1006	and
O	1007	1008	6
O	1009	1015	months
O	1016	1021	after
O	1022	1029	surgery
O	1029	1030	.

O	1031	1034	The
O	1035	1040	first
O	1041	1049	question
O	1050	1053	was
O	1054	1061	whether
O	1062	1065	the
O	1066	1073	patient
O	1074	1077	had
O	1078	1085	surgery
O	1085	1086	-
O	1086	1093	related
O	1094	1098	pain
O	1098	1099	.

O	1100	1102	If
O	1103	1111	answered
O	1112	1125	affirmatively
O	1125	1126	,
O	1127	1136	questions
O	1137	1141	from
O	1142	1145	the
O	1146	1153	Numeric
O	1154	1160	Rating
O	1161	1166	Scale
O	1167	1170	for
O	1171	1175	pain
O	1176	1178	at
O	1179	1183	rest
O	1184	1185	(
O	1185	1189	NRSr
O	1189	1190	)
O	1191	1194	and
O	1195	1198	for
O	1199	1207	coughing
O	1208	1209	(
O	1209	1213	NRSd
O	1213	1214	)
O	1215	1219	were
O	1220	1224	also
O	1225	1230	asked
O	1230	1231	.

O	1232	1235	Our
O	1236	1243	primary
O	1244	1251	outcome
O	1252	1255	was
O	1256	1259	the
B-outcome-Measure	1260	1269	incidence
I-outcome-Measure	1270	1272	of
I-outcome-Measure	1273	1277	PPSP
I-outcome-Measure	1278	1280	at
I-outcome-Measure	1281	1282	3
I-outcome-Measure	1283	1289	months
I-outcome-Measure	1290	1295	after
I-outcome-Measure	1296	1303	surgery
O	1303	1304	.

O	1305	1308	For
O	1309	1313	PPSP
O	1314	1322	analysis
O	1322	1323	,
B-total-participants	1324	1327	168
O	1328	1336	patients
O	1337	1341	were
O	1342	1350	included
O	1350	1351	.

O	1352	1355	The
B-outcome	1356	1362	number
I-outcome	1363	1365	of
I-outcome	1366	1374	patients
I-outcome	1375	1378	who
I-outcome	1379	1390	experienced
I-outcome	1391	1395	pain
O	1396	1399	was
O	1400	1413	significantly
O	1414	1419	lower
O	1420	1422	in
O	1423	1426	the
O	1427	1435	ketamine
O	1436	1441	group
O	1442	1444	at
O	1445	1446	3
O	1447	1453	months
O	1454	1455	(
B-cv-bin-percent	1455	1457	86
I-cv-bin-percent	1457	1458	.
I-cv-bin-percent	1458	1459	9
I-cv-bin-percent	1459	1460	%
O	1461	1463	in
O	1464	1467	the
O	1468	1475	control
O	1476	1481	group
O	1482	1484	vs
B-iv-bin-percent	1485	1487	69
I-iv-bin-percent	1487	1488	.
I-iv-bin-percent	1488	1489	0
I-iv-bin-percent	1489	1490	%
O	1491	1493	in
O	1494	1497	the
O	1498	1506	ketamine
O	1507	1512	group
O	1512	1513	,
O	1514	1515	P
O	1516	1517	=
O	1518	1519	.
O	1519	1522	005
O	1522	1523	)
O	1524	1539	postoperatively
O	1539	1540	.

O	1541	1548	However
O	1548	1549	,
O	1550	1553	the
B-outcome	1554	1558	NRSr
I-outcome	1559	1562	and
I-outcome	1563	1567	NRSd
O	1568	1571	did
O	1572	1575	not
O	1576	1582	differ
O	1583	1590	between
O	1591	1594	the
O	1595	1601	groups
O	1602	1612	throughout
O	1613	1616	the
O	1617	1623	follow
O	1623	1624	-
O	1624	1626	up
O	1626	1627	.

O	1628	1633	There
O	1634	1638	were
O	1639	1641	no
O	1642	1655	postoperative
O	1656	1659	low
O	1659	1660	-
O	1660	1664	dose
O	1665	1673	ketamine
O	1674	1682	infusion
O	1683	1689	groups
O	1690	1692	to
O	1693	1700	compare
O	1701	1704	due
O	1705	1707	to
O	1708	1716	hospital
O	1717	1728	regulations
O	1728	1729	.

O	1730	1736	Dosage
O	1737	1739	of
O	1740	1748	ketamine
O	1749	1752	was
O	1753	1756	too
O	1757	1760	low
O	1761	1763	to
O	1764	1770	reduce
O	1771	1774	the
B-outcome	1775	1783	severity
I-outcome	1784	1786	of
I-outcome	1787	1791	PPSP
O	1791	1792	.

O	1793	1796	And
O	1797	1799	by
O	1800	1805	using
O	1806	1814	propofol
O	1815	1818	and
O	1819	1831	remifentanil
O	1832	1835	for
O	1836	1846	anesthesia
O	1846	1847	,
O	1848	1857	different
O	1858	1865	results
O	1866	1869	can
O	1870	1872	be
O	1873	1880	deduced
O	1881	1885	with
O	1886	1894	volatile
O	1895	1906	anesthetics
O	1906	1907	.

O	1908	1912	Data
O	1913	1917	from
O	1918	1925	written
O	1926	1940	questionnaires
O	1941	1946	would
O	1947	1951	have
O	1952	1956	been
O	1957	1961	more
O	1962	1970	specific
O	1971	1975	than
O	1976	1985	telephone
O	1986	1996	interviews
O	1997	2000	for
O	2001	2005	long
O	2005	2006	-
O	2006	2010	term
O	2011	2021	assessment
O	2021	2022	.

O	2023	2029	Though
O	2030	2044	intraoperative
O	2045	2048	low
O	2048	2049	-
O	2049	2053	dose
O	2054	2062	ketamine
O	2063	2070	without
O	2071	2084	postoperative
O	2085	2093	infusion
O	2094	2107	significantly
O	2108	2115	reduced
O	2116	2119	the
O	2120	2129	incidence
O	2130	2132	of
O	2133	2137	PPSP
O	2138	2140	up
O	2141	2143	to
O	2144	2145	3
O	2146	2152	months
O	2153	2158	after
O	2159	2165	breast
O	2166	2172	cancer
O	2173	2180	surgery
O	2180	2181	,
O	2182	2184	it
O	2185	2191	failed
O	2192	2194	to
O	2195	2201	reduce
O	2202	2212	clinically
O	2213	2224	significant
O	2225	2229	PPSP
O	2230	2233	and
O	2234	2241	improve
O	2242	2250	patients
O	2250	2251	'
O	2252	2259	quality
O	2260	2262	of
O	2263	2267	life
O	2267	2268	.

O	2269	2278	Analgesia
O	2278	2279	,
O	2280	2286	breast
O	2287	2293	cancer
O	2293	2294	,
O	2295	2302	chronic
O	2303	2307	pain
O	2307	2308	,
O	2309	2317	ketamine
O	2317	2318	,
O	2319	2329	mastectomy
O	2329	2330	,
O	2331	2339	morphine
O	2339	2340	,
O	2341	2345	pain
O	2345	2346	,
O	2347	2360	postoperative
O	2360	2361	,
O	2362	2370	propofol
O	2370	2371	.
